Related Experiment Video
Updated: May 16, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Elevated Plasma MBL Levels Are Associated With Risk of Future Venous Thromboembolism: The HUNT Study
Christabel Esi Damoah1, Solveig M Valderhaug1, Omri Snir1,2
1Thrombosis Research Center, Department of Clinical Medicine (C.E.D., S.M.V., O.S., S.K.B., T.E.M., J.-B.H.), UiT-The Arctic University of Norway, Tromsø.
Background:
MBL (mannose-binding lectin), a pattern recognition molecule circulating in complex with MASPs (MBL-associated serine proteases), activates the lectin complement pathway and facilitates thrombin generation upon binding to specific moieties on pathogens or altered host cells. We aimed to investigate the association between plasma MBL levels and risk of future venous thromboembolism (VTE) and to explore the effect of MBL-MASP-1/2 complexes on thrombin generation.
Methods:
We conducted a population-based case-cohort (294 VTE patients, 1066 sex- and age-weighted subcohorts) derived from HUNT (The Trøndelag Health Study). Plasma MBL levels were measured using the SomaScan 7k aptamer-based platform. Cox proportional hazards regression models were used to estimate hazard ratios for VTE across quartiles of MBL levels. Thrombin generation in plasma induced by MBL-MASPs complexes was assessed in vitro.
Results:
Subjects with MBL levels in the highest quartile had a 79% higher risk of overall VTE (hazard ratio, 1.79 [95% CI, 1.23-2.61]) than those with MBL levels in the lowest quartile after multivariable adjustments. The risk estimates by high plasma MBL were particularly strong for deep vein thrombosis (hazard ratio, 2.50 [95% CI, 1.42-4.37]) and unprovoked VTE (hazard ratio, 2.81 [95% CI, 1.53-5.16]). MBL-MASP-1/2 complexes promoted complement activation and thrombin generation, and monospecific inhibitors abolished their enzymatic activity.
Conclusions:
Our findings support the notion that high plasma MBL levels are associated with an increased risk of future VTE and suggest that the risk increase is partially mediated through the initiation of thrombin generation by MBL-MASP-1/2 complexes at the site of venous thrombosis formation.
Insights
High levels of mannose-binding lectin (MBL) are linked to a significantly increased risk of venous thromboembolism (VTE). This elevated risk appears to be partly due to MBL-associated serine proteases initiating thrombin generation.
Area of Science:
- Immunology
- Complement System
- Thrombosis
Background:
- Mannose-binding lectin (MBL) is a pattern recognition molecule that activates the lectin complement pathway.
- MBL circulates with MBL-associated serine proteases (MASPs) and can facilitate thrombin generation.
- Binding of MBL to pathogens or altered host cells initiates these processes.
Purpose of the Study:
- To investigate the association between plasma MBL levels and the future risk of venous thromboembolism (VTE).
- To explore the role of MBL-MASP-1/2 complexes in promoting thrombin generation.
Main Methods:
- A population-based case-cohort study (HUNT study) involving 294 VTE patients and 1066 subcohorts.
- Plasma MBL levels were quantified using a SomaScan 7k aptamer-based platform.
- Cox proportional hazards regression models were used to assess VTE risk, and in vitro assays examined thrombin generation by MBL-MASP complexes.
Main Results:
- Individuals in the highest quartile of MBL levels had a 79% increased risk of overall VTE compared to the lowest quartile.
- High MBL levels were strongly associated with increased risk for deep vein thrombosis (HR 2.50) and unprovoked VTE (HR 2.81).
- MBL-MASP-1/2 complexes were shown to promote complement activation and thrombin generation in vitro.
Conclusions:
- Elevated plasma MBL levels are associated with a higher risk of future VTE.
- The increased VTE risk may be partly mediated by MBL-MASP-1/2 complexes initiating thrombin generation at the site of clot formation.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Esophageal Varices-I: Introduction

